Problem

Drug discovery is slow, expensive, and failure-prone: InVirtuoLabs cites development timelines averaging roughly 12 years and costs exceeding €2.4 billion per drug. The company targets the early-stage bottleneck of identifying viable molecules and turning them into optimized drug candidates, where researchers must search enormous chemical spaces while balancing efficacy, safety, and drug-like properties.

Its clearest use case is applying generative AI and molecular simulation to produce and test billions of candidate molecules, initially for therapeutic targets such as nuclear receptors involved in metabolic disease. The company says its approach can improve success rates while materially reducing the time and cost of discovery.

Product / Service

InVirtuoLabs is building a proprietary “Next Generation Virtual Lab” that combines multimodal and active machine learning, generative chemistry, and physics-based molecular simulations. Its modular platform includes InVirtuoMOL for molecular machine learning, InVirtuoGEN for generating and optimizing novel molecules, and InVirtuoSIM for evaluating molecular properties and drug-target interactions at scale.

The delivery model combines internal drug-discovery programs with pharma co-development. In a February 2026 collaboration, Helsinn supplied a proprietary compound library and InVirtuoLabs applied InVirtuoGEN to design, optimize, and prioritize new candidates for potential preclinical development. The intended benefit is faster hit-to-lead progression, broader exploration of chemical space, and more efficient selection of compounds worth testing in the laboratory.

Market

InVirtuoLabs operates in AI-native drug discovery and computational chemistry, overlapping with virtual-lab and AI-enabled therapeutics companies such as Recursion, Isomorphic Labs, insitro, and XtalPi. Its differentiation is the combination of generative chemistry with physics-based simulation and an emphasis on both proprietary drug programs and collaboration with pharmaceutical companies, rather than merely selling a standalone software tool.

The company appears to be an early-stage, pre-commercial biotech rather than a business with a marketed drug or disclosed product revenue. It was founded in 2024, closed a €2.85 million pre-seed round in February 2025, won the 2024 Boldbrain Startup Challenge, and announced a strategic R&D collaboration with Helsinn in February 2026. By July 2026 it was also leading the €2.3 million Eurostars-funded NeuroSpark project for virtual-cell-based neurodegenerative drug discovery. Public materials do not disclose revenue, but these financings, partnerships, and research programs indicate meaningful early validation and a pipeline still progressing toward preclinical development.